New hope for medicine: So Boten-RNA remains stable and healing!
New hope for medicine: So Boten-RNA remains stable and healing!
In a significant scientific discovery, researchers from the Max Planck Institute for Molecular Physiology have developed a new class of mRNA-stabilizing substances. This innovation could represent a decisive progress in the development of mRNA-based therapeutic agents and vaccines that are considered a promising solution in the fight against various diseases.Boten-RNA, or mRNA, plays a central role in cell metabolism, since it transports the genetic information from cell nucleus to the protein factories in the cell plasma. One of the challenges when using mRNA in therapies lies in efficient stabilization, since healthy mRNA is quickly broken down. This can lead to the fact that less of a required protein is produced. Therefore, stabilizing health-promoting mRNA molecules is crucial for the success of future treatments.
new approaches to stabilize mrna
The team around Peter 't Hart has developed a promising strategy that inhibits the Deadenylation of the mRNA. This process, in which adenin-nucleotides are removed from the mRNA, leads to the destruction of the messenger RNA. In tests it was shown that the newly developed active ingredient can block the interaction of the target mRNA with the CCR4-not complex, which could significantly extend the lifespan of the mRNA.
The challenge was to create a large peptide that reaches this blockade. Such peptides often find it difficult to penetrate cell membranes. Through targeted chemical modifications, however, the researchers have managed to improve the bioavailability of the peptide. This means that the peptide can work more effectively in cells, which is decisive for potential therapeutic applications.
The stabilization of two promising proteins could already be demonstrated in living cells: a tumor -uppressor that plays a role in combating cancer, and a nuclear receptor that could possibly be beneficial in the treatment of age -related illnesses. These results demonstrate the potential of the new method for stabilizing health -promoting mrnas.'t explains: "The concept of stabilizing health -promoting mrnas by preventing your deadylation is new and could be pioneering for the development of new medication." The team will continue to work on other inhibitors to further develop this promising technology.
For the in -depth examination of this research, the team published an article entitled: "Stapled Peptides as inhibitor of mrna Deadenylation", which contains many details about their methods and results. This study could be the beginning of a new age in mRNA-based therapy development, since it lays the foundation for future innovative treatments that specifically target diseases, for which there are only limited therapeutic approaches. It remains to be seen how this findings will affect research and development in the area of MRNA therapies, but progress is promising.
Further information on the background of this research work can be found here
| Details | |
|---|---|
| Ort | Max-Planck-Institut für molekulare Physiologie, 44139 Dortmund, Deutschland |
Kommentare (0)